A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer

Published:2020-10-16 Issue: Volume:26 Page:
ISSN:1643-3750
Container-title:Medical Science Monitor
language:en
Short-container-title:Med Sci Monit

Author:

Cui Hanzhi¹,Guan Jingzhi²,Deng Guochao²,Yuan Jiajia³,Lou Changjie⁴,Zhang Wen⁵,Zhou Aiping⁵,Zhang Yanqiao⁴,Zhou Jun³,Dai Guanghai⁶

Affiliation:

1. Medical School of Chinese People’s Liberation Army (PLA), Beijing, China (mainland)

2. Department of Oncology, The Eighth Medical Center, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China (mainland)

3. Department of Oncology, Beijing Cancer Hospital, Beijing, China (mainland)

4. Department of Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China (mainland)

5. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (mainland)

6. Department of Oncology, The First Medical Center, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China (mainland)

Publisher

International Scientific Information, Inc.

Subject

General Medicine

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival outcome of different treatment sequences in patients with locally advanced and metastatic pancreatic cancer;BMC Cancer;2024-01-12

2. [18F] AlF-NOTA-FAPI-04 PET/CT can predict treatment response and survival in patients receiving chemotherapy for inoperable pancreatic ductal adenocarcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2023-06-17

3. Real-world dose reduction of standard and modified FOLFIRINOX in metastatic pancreatic cancer: a systematic review, evidence-mapping, and meta-analysis;Therapeutic Advances in Medical Oncology;2023-01

4. Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data;Neoplasia;2022-12

5. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study;Cancer Control;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3